Alzheimer's Drug Controversy
The FDA's approval of adrakinumab raises significant concerns, particularly regarding its hefty price tag of $56,000 per year amidst limited efficacy. With Alzheimer's affecting over 6 million Americans and projected to rise, the financial burden on Medicare and caregivers becomes increasingly alarming. Many caregivers, often family members, struggle to provide care without adequate financial support, highlighting the urgent need for more effective and affordable treatment options.In this clip
From this podcast
Psychiatry & Psychotherapy Podcast
Alzheimer’s Dementia
Related Questions